Maddela Soumya, Sk. Khasim, R. Kasturi, Srinivas Kumar Arramraju, N. Mudgalkar, A. Baviskar
{"title":"Efficacy of Ibutilide for Terminating Recent Onset Atrial Fibrillation- A Single Centre Study","authors":"Maddela Soumya, Sk. Khasim, R. Kasturi, Srinivas Kumar Arramraju, N. Mudgalkar, A. Baviskar","doi":"10.47799/pimr.0902.16","DOIUrl":null,"url":null,"abstract":"Introduction:\nIbutilide is a class 3 antiarrythmic agent that is used\ninfrequently. There are few studies on its usage, especially\namong Indians.\nMaterials & Methods: A retrospective study was conducted\non patients in a tertiary care unit who had recently developed\natrial fibrillation and were given the normal dose of ibutilide.\nDuring the study period, data was gathered from medical\nrecords.\nResults: During the study period, ibutilide was given to a total\nof 40 patients who met the inclusion criteria. The majority of\nthe participants were under 60 years old and had only been in\natrial fibrillation for less than 24 hours. In 70% of cases, atrial\nfibrillation could be successfully terminated with only a small\nrisk of adverse events.\nConclusion: Ibutilide is a safe and effective treatment for\npeople who have recent onset atrial fibrillation.","PeriodicalId":30624,"journal":{"name":"Perspectives In Medical Research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perspectives In Medical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47799/pimr.0902.16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction:
Ibutilide is a class 3 antiarrythmic agent that is used
infrequently. There are few studies on its usage, especially
among Indians.
Materials & Methods: A retrospective study was conducted
on patients in a tertiary care unit who had recently developed
atrial fibrillation and were given the normal dose of ibutilide.
During the study period, data was gathered from medical
records.
Results: During the study period, ibutilide was given to a total
of 40 patients who met the inclusion criteria. The majority of
the participants were under 60 years old and had only been in
atrial fibrillation for less than 24 hours. In 70% of cases, atrial
fibrillation could be successfully terminated with only a small
risk of adverse events.
Conclusion: Ibutilide is a safe and effective treatment for
people who have recent onset atrial fibrillation.